Lactoferrin: potential functions, pharmacological insights, and therapeutic promises

Kazi Ahsan Ahmed1,2, Abu Saim Mohammad Saikat1,3, Akhi Moni1, Sadia Akhter Mallik Kakon1, Md. Rashedul Islam3, Md Jamal Uddin1,4*

1ABEx Bio-Research Center, East Azampur, Dhaka-1230, Bangladesh
2Department of Biochemistry and Molecular Biology, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh
3Department of Genetics and Animal Breeding, Faculty of Veterinary and Animal Science, Hajee Mohammad Danesh Science and Technology University, Dinajpur-5200, Bangladesh
4Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea

ABSTRACT

Lactoferrin (LF) is an iron-binding multifunctional glycoprotein, act as a natural protective agent. In general, LF is involved in various physiological activities, including antibacterial, antifungal, antiviral, antiparasitic, anticarcinogenic and iron metabolism. The LF is most frequently found in milk as well as many other exocrine secretions such as saliva, bronchial mucus, seminal fluids, and gastrointestinal fluids, respectively. Increased expression and secretion of LF may play a significant role in the first line of host defense. One of the primary functions of LF is to scavenge free iron in fluids and inflamed areas to avoid free radical-facilitated damage. LF influences the proliferation, maturation, and activity of immune cells at the cellular level. LF plays a significant protective role in inflammation, oxidative stress, fibrosis, endoplasmic reticulum (ER) stress, autophagy dysfunction, and mitochondrial dysfunction. Also, LF was found protective against various pathologies including anemia, sepsis, and diarrhea in clinical settings. This article reviews the protective role of LF against different pathophysiological conditions and its therapeutic advances as well as further research prospects.

INTRODUCTION

Lactoferrin (LF) is a glycoprotein and a part of the transferrin family, formerly known as lactotransferrin. These proteins conjugate and transfer Fe3+ ions [1]. LF is one of the essential components of the body’s immune system, primarily a member of mucosal innate defenses [2]. LF is a component of the iron-resistant immune system incorporated in vertebrate species to detoxify and sequester toxic metals [3]. LF was first isolated from bovine milk by Sorensen and Sorensen in 1939. In 1960, it was simultaneously determined by three independent laboratories as the main iron-binding protein in human milk with a higher concentration in colostrum (range 6–7 g/L) than in mature milk (range 2 g/L) [1][4]. LF existing in mammalian milk, tears, saliva, cerebrospinal fluid, and other excretory fluids [4] is a 78-kDa glycoprotein, folded into two globular lobes with a single amino acid chain. Each lobe is connected to a 3-kDa glycan chain via an N-glycosidic linkage. These lobes bind to each of the iron-binding sites firmly with the active residue being two tyrosines, a histidine, and an aspartate [3]. LF is excreted from the exocrine glands and identified in particular granules of neutrophils. At the end of degranulation, neutrophils are the primary source of LF in blood plasma.

LF provides non-specific protection against pathogens and other pathologies due to its antimicrobial, anti-inflammatory, and anticancer properties, and it is an important component of mammalian innate immunity [5]. It has broad spectrum of biological functions, including cell proliferation and differentiation, iron...
metabolism, antiparasitic, antifungal, antiviral, and antibacterial activities [1]. LF played an important role in defense mechanisms by the chelating of iron. Since bacteria require iron to grow, LF can inhibit them by chelating it [6]. Inflammation is a vital part of the host’s protection against bacterial infection. Seeking new therapeutics is important in the fight against infectious diseases. A milk derivative known as bovine LF (bLF) has recently been discovered to be an effective regulator of iron and inflammatory homeostasis, with a strong effect on reducing inflammatory host responses [7]. Furthermore, several studies have reported the antioxidant effect of LF, and binding affinity of LF to the cells, which limit the membrane lipid peroxidation process because LF is not fully saturated and can scavenge free iron radicals that are cytotoxic activators of the lipid peroxidation and oxidative stress and suppresses free radical-mediated damage [8]. LF, a nutraceutical protein, is implicated in certain immunogenic processes and has been suggested to play a part in neurodevelopment and neuropathy [9]. Recently, LF has been suggested as potential preventative and adjunct treatment for COVID-19 [10]. These observations of LF indicate that it may have significant therapeutic potential, and this review was intended to deliver an insight of scientific information on this biomolecule and its activities.

### METHODS

The literature was collected by searching the published research articles from PubMed, Google Scholar, and Scopus. To conduct the searching, we used several keywords such as LF vs “structure, sources, functions, inflammation, oxidative stress, fibrosis, endoplasmic reticulum stress, autophagy dysfunction, and mitochondrial dysfunction”. Also, we used ClinicalTrials.gov to find out recent clinical trials on LF. Figures were generated using BioRender.com.

#### Table 1. The composition of amino acids and the secondary structural elements of Human (Homo sapiens) and Bovine (Bos taurus) LF.

<table>
<thead>
<tr>
<th>Amino Acid composition</th>
<th>Human</th>
<th>Bovine</th>
<th>Human</th>
<th>Bovine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala (A)</td>
<td>65 (9.2%)</td>
<td>70 (9.9%)</td>
<td>Leu (L)</td>
<td>66 (9.3%)</td>
</tr>
<tr>
<td>Arg (R)</td>
<td>44 (6.2%)</td>
<td>37 (5.2%)</td>
<td>Lys (K)</td>
<td>46 (6.5%)</td>
</tr>
<tr>
<td>Asn (N)</td>
<td>32 (4.5%)</td>
<td>29 (4.1%)</td>
<td>Met (M)</td>
<td>6 (0.8%)</td>
</tr>
<tr>
<td>Asp (D)</td>
<td>38 (5.4%)</td>
<td>36 (5.1%)</td>
<td>Phe (F)</td>
<td>32 (4.5%)</td>
</tr>
<tr>
<td>Cys (C)</td>
<td>33 (4.6%)</td>
<td>35 (4.9%)</td>
<td>Pro (P)</td>
<td>35 (4.9%)</td>
</tr>
<tr>
<td>Gin (Q)</td>
<td>29 (4.1%)</td>
<td>29 (4.1%)</td>
<td>Ser (S)</td>
<td>50 (7.0%)</td>
</tr>
<tr>
<td>Glu (E)</td>
<td>41 (5.8%)</td>
<td>40 (5.6%)</td>
<td>Thr (T)</td>
<td>31 (4.4%)</td>
</tr>
<tr>
<td>Gly (G)</td>
<td>56 (7.9%)</td>
<td>51 (7.2%)</td>
<td>Trp (W)</td>
<td>10 (1.4%)</td>
</tr>
<tr>
<td>His (H)</td>
<td>9 (1.3%)</td>
<td>10 (1.4%)</td>
<td>Tyr (Y)</td>
<td>21 (3.0%)</td>
</tr>
<tr>
<td>Ile (I)</td>
<td>16 (2.3%)</td>
<td>16 (2.3%)</td>
<td>Val (V)</td>
<td>50 (7.0%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary structural elements</th>
<th>Human</th>
<th>Bovine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha helix</td>
<td>228 (32.11%)</td>
<td>231 (32.63%)</td>
</tr>
<tr>
<td>Beta turn</td>
<td>45 (6.34%)</td>
<td>38 (5.37%)</td>
</tr>
<tr>
<td>30 helix</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Bend region</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Phi helix</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Random coil</td>
<td>308 (43.38%)</td>
<td>306 (43.22%)</td>
</tr>
<tr>
<td>Beta bridge</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Other states</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>Extended strand</td>
<td>129 (18.17%)</td>
<td>133 (18.79%)</td>
</tr>
</tbody>
</table>

### POTENTIAL FUNCTIONS OF LACTOFERRIN

**Source**

LF exists in biological liquids such as milk, seminal fluid, and saliva [6]. It also exists on mucosal surfaces as well as in some granules found in polymorphonuclear leukocytes. Human milk, as well as bovine milk, are the most plentiful source of LF. LF concentrations in milk vary significantly from one lactation period to another. LF concentrations in colostrum varies in different species with humans having 5.80 ± 4.30 mg/mL [11], bovine0.82 ± 0.54 mg/mL [12], goat 0.39 ± 0.07 mg/mL [13], camel0.81 ± 0.31 mg/mL [14] of LF, respectively. Additionally LF can also be found in different concentrations in human milk 2.00 – 3.30 mg/mL [11], bovine milk 0.03 – 0.49
mg/mL [6], goat milk 0.17 - 0.59 mg/mL [15], camel milk 0.06 – 0.89 mg/ml [14], and human tears 1.13 ± 0.29 mg/mL [16], respectively.

Structure

LF is comprised of a glycoprotein-rich polypeptide chain with a weight of approximately 78 kDa. Detailed structural studies have shown that in the human and bovine LF, there are respectively 691 and 696 amino acids [17][18]. LF has an analogous sequence of amino acids from mammalian species. Bovine and human LF have a similarity in structure of about 70 percent, and chimpanzee and human LF share nearly 97 percent [19]. Human and bovine LFs amino acids (AA) composition and secondary structural elements are represented in Table 1.

The protein sequence of LF present in human and bovine was collected from the UniProtKB server (https://www.uniprot.org/) with the accession IDs of P02788, and B9VPZ5, respectively. The ProtParam server (https://web.expasy.org/protParam/) and the NPS-SOPMA server (https://nps-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=NPSA/npsa_sopma.html) were executed to calculate the amino acid composition and the secondary structural elements, accordingly.

Functions

In this section, we have summarized various function of LF as below and in the Figure 1.

Iron metabolism

Iron is a cofactor for vital enzymes involved in many fundamental cell functions and metabolic pathways. Iron insufficiency can lead to reduced immunity and fatigue [20][21]. LF has an excellent iron affinity with a constant balance dissociation (KD) of approximately 10^-20 and is required to maintain a regular iron harmony and eliminate iron deficiency and iron overload. In the presence of two molecules of carbonate ions (CO$_3^{2-}$), two ferric ions (Fe$^{3+}$) can bind with one LF molecule [22], thus acting as an iron transporter in the iron recycling process, which is why numerous studies demonstrated therapeutic benefits and the nutritional advantages of LF [23][20][24]. Oral delivery of bovine LF is effective in preventing anemia in pregnant women [25]. Therefore, LF can be a significant iron source for people with iron deficiency [26].

Antibacterial properties

Numerous widely diversified LF-sensitive pathogens have proved to have bactericidal and/or bacteriostatic impact [27]. One of the factors that underlie LF’s bacteriostatic behavior is its ability to bind vast quantities of iron and inhibit its use for development by microorganisms [28]. The bactericidal function of LF occurs predominantly by direct contact with bacterial surfaces by interfering with the lipopolysaccharide (LPS) lipid A and its eventual neutralization by which the Gram-negative bacterial membrane’s permeability may be impaired [28]. LF also has bactericidal and bacteriostatic properties and has a wide range of inhibitions, especially in Bacillus stearothermophilus [29], Staphylococcus aureus [30], Bacillus subtilis [31], Streptococcus parasanguinis [32] of gram-positive bacteria; and Chlamydophila psittaci [33], Haemophilus influenzae [34], Vibrio cholerae [35], Mycobacterium tuberculosis [36][37], Salmonella enteritidis [38] of gram-negative bacteria. By interacting with LPS, LF can conflict with bacterial attachment and thus prevent one of the vital virulence effects of these microorganisms [39][40][27].

Antifungal properties

The broad array of LF antifungal activity against mold and yeast is now well documented [41][42]. Owing to their powerful iron (Fe$^{3+}$) scavenging effects, LF and its related peptides can effectively function on a diverse array of fungal organisms. LF has been reported to have antifungal potentials against Candida kruzie, Candida albicans, and Aspergillus fumigatus [43][44]. In addition to its iron-depriving activity, LF attaches to the cell’s fungal surface followed by destroying the layer, and enhances the cell membrane’s permeability, resulting in death of the organism. Because of these attributes, LF is included in a variety of antifungal therapies, such as those required to treat oral candidiasis [45].

Antiviral properties

LF is a broad spectrum antiviral agent that effectively prevents naked and coated DNA and/or RNA viruses from infecting animals and humans [46][47]. The LF
domain that functions against viral infections is distinct from that of bacteria. LF bacteriostatic peptide was not observed as being selective for viruses [46], therefore LF antiviral activity is well demonstrated against a broad range of viruses, including herpesvirus, human immunodeficiency virus (HIV), friend virus complex (FVC), human hepatitis B virus (HBV), human hepatitis C virus, parainfluenza virus (PIV), respiratory syncytial virus (RSV), alphavirus, hantavirus, human papillomavirus (HPV), rotavirus, adenovirus, and picornavirus [48].

Figure 1. Functions of lactoferrin. This diagram depicts lactoferrin’s diverse biological roles, which include iron metabolism, antiparasitic, anticarcinogenic, antiviral, antifungal, and antibacterial properties. Its ability to metabolize iron aids in maintaining homeostasis and preventing anemia, as well as providing other therapeutic benefits. Lactoferrin’s antiparasitic properties have been linked to immune cell proliferation, which aids in parasitism prevention. Its anticarcinogenic effects inhibit carcinogenesis via several cancer pathway alterations. Lactoferrin has antiviral characteristics that resist such naked and coated DNA and/or RNA viruses of both animals and humans effectively. It has antifungal potential against a variety of fungi and is used as an antifungal therapy. Lactoferrin’s bactericidal activity has demonstrated promising results against gram-positive and gram-negative bacteria, as well as inhibiting bacterial attachment.
Antiparasitic properties

LF’s antiparasitic commitment is different and varies between species. The noteworthy underlying mechanism in many of these parasites is the sequestration of iron, which plays a prominent part in hosting parasites. Numerous investigations indicated that the T-cell reaction is enhanced as an intervention mechanism [49]. The improvement in T CD4 + lymphocytes after LF is administered to both immunocompetent and immunosuppressed mice before Toxoplasma Gondii infections have been reported. However, on the contrary, many parasites, including Trichomonas vaginalis and Trichomonas fetus use LF for development [28].

Anticarcinogenic properties

LF enforces antineoplastic involvement through various cancer-type response pathways, such as altering the cell membrane, cell immunomodulation, metastasis inhibition, cell cycle arrest, antiangiogenic action, apoptosis induction, and cell necrosis. LF’s chelating involvement is by far the most extensively reported biological mechanism towards tumor development. Oxidative stress (OS) on genetic material is found to increase iron in the tissue, which induces carcinogenesis, and thus, LF prevents this by trapping this ion on the surface of the tissue [50].

PHARMACOLOGICAL POTENTIALS OF LACTOFERRIN AGAINST VARIOUS PATHOLOGICAL CONDITIONS

LF is a cell-secreted mediator that links innate and adaptive immunity in mammals [51]. LF binding affects the target cells in a cellular signaling pathway and activates target genes [52]. The pharmacological potential of LF against various pathological conditions such as oxidative stress, inflammation, fibrosis, endoplasmic reticulum (ER) stress, autophagy dysfunction, and mitochondrial dysfunction (Figure 2).

Inflammation

Inflammation is an adaptive response that involves a wide range of physiological and pathological processes stimulated by noxious stimuli and conditions [53][54]. It is a complex interaction between soluble components and cells in any tissue in reply to traumatic, infectious, post-ischemic, toxic, acute kidney injury or autoimmune injury [55-57]. LF is known to be up regulated in inflammatory diseases, including inflammatory bowel disease, allergic skin, lung disorders, neurodegenerative disease, and arthritis [52].

LF acts as a natural regulator of host defense [51] with significant anti-inflammatory activities related to the scavenging of free iron that accumulates in inflamed tissue and catalyzes the production of tissue-toxic hydroxyl radicals, making LF a potent therapeutic candidate in the treatment of common inflammatory diseases [58]. LF is one of the first factors expressed by neutrophils after exposure to pathogens and contributes to innate activation of adaptive responses [51] by releasing active neutrophils into the site of inflammation. The concentration of LF in the blood is usually low(0.2–0.6 g/ml), and may increase significantly due to exposure to neutrophils at the inflammation site and exceed 200 g/ml [59]. It has been demonstrated that LF may inhibit inflammation related to microbial challenge [52] and also been reported to bind to bacterial endotoxin lipopolysaccharides (LPS), a key mediator of the inflammatory response to bacterial infections.

Consequently, the interaction of LPS with receptors is disrupted, and events such as the upregulation of inflammatory cytokines are reduced [60]. In vitro studies have shown LF administration to protect the gut mucosal integrity induced by LPS challenge, gastritis from Helicobacter pylori, and endotoxemia and lethality in response to systemic challenge with E. coli or LPS. Studies on monocytes suggest that LF’s anti-inflammatory activity in response to the challenge of LPS may inhibit pro-inflammatory cytokine synthesis after LF translocation into the nucleus by inhibiting NF-kB activation [52].

Another possible role of LF is removing free iron in inflammatory centers e.g. rheumatoid joints, by preventing the catalysis of harmful free radicals [60]. Rheumatoid arthritis patients often have iron deposits in their synovia which when bound with LF, cannot react with superoxide to produce injurious hydroxyl radicals that cause vital tissue damage in rheumatoid arthritis. LF has been injected intra-articularly into animal models of inflammation and has been reported to inhibit inflammation. Therefore, LF’s local administration and consequence of increased LF in the synovium is initially thought to be anti-inflammatory and may be effective in the treatment of rheumatoid arthritis [59].
Fascinatingly, in neurodegenerative diseases where iron accumulation contributes to oxidative stress and neuronal death, excessive expression of LF in some regions of the brain has been reported [61]. This phenomenon may play a role in limiting oxidative stress in the brain with transcytosis of plasma LF by the blood-brain barrier during inflammation [58][62].

In vivo studies have shown that LF can protect against skin and lung allergies [63][64]. LF is highly expressed in allergic patients [65], a mechanism that contains the activation of mast cells and basophils and IL-1β and TNF-α-triggered translocation of antigen-presenting cells. In skin allergies, a mechanism has been proposed that LF binds to keratinocytes and prevents the release of TNF-α from those cells [66]. LF can reduce cutaneous inflammation by inhibiting the migration of Langerhans cells [60]. In humans and mice, it is shown that LF protects from IL-1β induced cutaneous inflammation and inflammatory bowel disease that chemically influenced. In many cases, this protection was significantly associated with an increase in anti-inflammatory cytokines, including IL-10, and a decrease in pro-inflammatory cytokines, including TNF-α and IL-1β. The capability of LF to interact with specific receptors in several immune cells, including monocytes, macrophages, neutrophils, and in addition to epithelial cells, indicates that the anti-inflammatory activity of LF may be an outcome of a direct effect on modulating cytokine production by these cells via receptor-facilitated signaling pathways [52].

LF is called first-line defense glycoprotein due to its protection system against the progression of systemic inflammatory response syndrome (SIRS) and sepsis. The clinical significance of LF in controlling these processes has been demonstrated through studies based on neonates, where dietary supplementation with LF has reduced the incidence of late-onset sepsis. LF has proven to be a primary innate immune modulator that plays a crucial role in controlling acute septic inflammation [60]. In the case of infection, the systemic monocyte or macrophage reacts with the generation of inflammatory mediators, which then persuades bone marrow to form new immune cells and trigger the degranulation of mature neutrophils. Consequently, a vast amount of LF is released from neutrophil’s secondary granules to fight infection [60]. Thus, the anti-inflammatory effects of LF signify a systematic sequence of events during the development of acute inflammation and could be seen as a further manifestation of the role of neutrophils in inflammation [60][67].

**Oxidative stress**

An imbalance of pro-oxidants and antioxidants is called oxidative stress, which is portrayed as a disturbance of redox signaling and control mechanisms [68]. Oxidative stress arises when free radical levels exceed the cell’s ability to fight them causing an imbalance between free radical production and the antioxidant defense system [69]. It can occur due to exposure to reactive oxygen mediators, which can damage proteins, nucleic acids, and cell membranes[70]. Free iron radicals are toxic, damaging cellular components, or producing reactive oxygen species (ROS) that are cytotoxic [71]. Antioxidants can reduce oxidative damage and improve life quality by preventing or delaying the onset of degenerative diseases.

bLF, with its iron-binding capability, appeared as antioxidant activity [72] and was considered an antioxidant [73-75], and LFs from other animal sources, such as humans [76] and camels [77], showed antioxidant activity too [78]. According to iron sequestration, LF regulates the physiological balance of ROS production and their exclusion rate that naturally protects from oxidative cell injury.

On the other hand, the superoxide radical can undergo a two-step, non-enzymatic degradation process in the presence of free ferric ions (Fe³⁺) [67]. In the first step, a superoxide molecule responds with ferric ion (Fe³⁺), generates ferrous salt (Fe²⁺) and the ground state oxygen. In the second step, ferrous (Fe²⁺) ions react with hydrogen peroxide generates ferric salt (Fe³⁺), a hydroxyl radical, and alcohol, which is known as the Fenton reaction [67]. Microbicidal activity is strongly involved in phagocytic and lipid peroxidation events, especially in polyunsaturated fatty acids, to form hydroxyl radicals through an iron-dependent reaction. The reaction of the hydroxyl radical with polyunsaturated fatty acids results in the notion of a hydrogen atom. It begins the lipid peroxidation and the formation of intermediates like hydroxyalkenals. These new radicals can induce functional alterations in many biologically essential macromolecules, including DNA, proteins, and lipids. LF aids in the sequestering of ferric (Fe³⁺) ions to protect from oxidative stress's harmful effects [67].
The tissues of the anterior part of the eye are mainly susceptible to oxidative stress, and they have developed numerous antioxidant defense mechanisms to avoid injury. Deficiencies in the antioxidative apparatus and immune systems are involved in various ocular pathologies, for example, keratoconus (KC), dry eye, and Sjögren syndrome [79]. Tear fluid contains antioxidative compounds such as LF, vitamin C, glutathione, and superoxide dismutase (SOD), which protect the corneal epithelium against the effects of ultraviolet irradiation, chemical agents, and direct airflow [79]. The main antioxidant molecules in the cornea are enzymes superoxide dismutase catalase, and glutathione peroxidase. Besides, the synthesis of reactive oxygen and nitrogen species can be noticed in KC tissues. Significantly, the decline of antioxidant molecules was observed in the KC cornea compared to healthy corneas. Besides, LF is a protein with vital antioxidant activity, is present in the tears of high concentration (1.1 ± 0.3 mg/mL vs. 7.0 ± 1.6 mg/mL, total tear protein content). This natural defense against oxidative stress can play a crucial role in preventing such eye disorders progression [79].

Mainly in human medicine, bLF is used as a food additive due to its availability that designated by the U.S. Food and Drug Administration, which is generally recognized as safe [71]. The bLF can regulate the physiological balance of ROS generation and their elimination rate by iron sequestration. Many researchers have proven that bLF is capable of modulating the adaptive immune response and that it has crucial regulatory activity in cellular redox through the uptake of vital antioxidant enzymes [80-83]. It is shown that oral supplementation of bLF enhances total, helper, and cytotoxic T-cell activation and hydrophilic antioxidant status. The bLF may otherwise be a useful nutritional supplement to support immunity and antioxidant status in healthy individuals [73].

LF can protect human mesenchymal stem cells against oxidative stress-induced senescence and apoptosis [84]. Mesenchymal stem cells (MSCs) have been proposed as a crucial candidate for cell therapy due to their ability to self-regulate and differentiate. MSCs poorly live after exposure to environmental factors such as oxidative stress and endure senescence or apoptosis when transplanted. The clinical application of these cells is still limited due to its survival issue. Therefore, the effectiveness of MSC therapy can be improved by reducing oxidative stress through LF administration. The study revealed that pretreatment of LF is effective against oxidative stress-induced senescence and apoptosis of human MSCs (hMSCs). ROS measurement discovered that LF inhibited hydrogen peroxide-induced senescence of hMSCs by inhibiting caspase-3 and Akt activation [84].

Oxidative stress has also been associated with pregnancy complications. Administration of LF to the vagina reduced the oxidative stress of amniotic fluid (AF) in pregnant women with mid-trimester genetic amniocentesis. Thus, the stable generation of ROS is crucial for various reproductive processes, from oocyte maturation to fetal development to delivery stimulation [85][86]. Oxidative stress may lead to a variety of pregnancy-related complications directly or indirectly, for example, spontaneous abortion, recurrent miscarriage, preterm labor, and preterm pre-labor rupture of membranes (PPROM) [87]. Vaginal LF administration can control the expression of inflammatory markers and matrix metalloproteinases (MMPs), intensely associated with preterm labor, pre-labor rupture of membranes, and PPROM [88-90]. It reduces oxidative stress assessed in pregnant women’s amniotic fluid enduring mid-trimester genetic amniocentesis [91]. As the LF enters into the amniotic sac, it can reduce lipoperoxides production by directly mediating intermediate ROS scavenging or eliminating Fe3+ from the Fenton reaction [92][94]. Transvaginal LF can directly exert an immunomodulatory effect through modulating the in vivo and in vitro ROS generation. LF can limit oxidative stress by interfering with lipid peroxidation products formation. LF can be used as a therapeutic to treat pregnancy-related complications [91].

**Fibrosis**

Fibrosis is defined as excessive growth, stiffness, or scarring of several tissues and is identified as causing excessive deposition of extracellular matrix components, including collagen. Fibrosis is the final result of chronic inflammatory reactions stimulated by various stimuli, including persistent infections, autoimmune reactions, allergic reactions, chemical insults, radiation, and tissue injuries [93]. LF plays an antifibrotic role in human kidney proximal tubular cells. Excess matrix proteins, fibroblasts accumulation, and nephrons functional damage are the leading pathological features of progressive CKD and the cause of renal fibrosis. Transforming growth factor-β1 (TGF-β1) is an essential mediator in renal fibrosis [94]. Connective tissue growth factor (CTGF) and...
plasminogen activator inhibitor-1 (PAI-1) are known to be effective inducers of tissue fibrosis. It is documented that TGF-β1 amplifies CTGF, PAI-1, and collagen I in a concentration-dependent manner.

To scrutinize the capabilities of LF against fibrosis, stimulated cultured renal epithelial cells (HK-2) with TGF-β1 were observed in the presence or absence of LF to examine whether LF prevents the TGF-β1 induced fibrosis signaling pathway. The investigation exhibited that LF decreased the profibrogenic TGF-β1 target genes PAI-1, CTGF, and collagen I thus indicating that LF inhibits TGF-β1-induced renal fibrosis [94].

Liver fibrosis is the most crucial pathological concern of all chronic liver diseases. Certain drugs, autoimmune disorders, and genetic diseases are the significant causes of liver fibrosis. Antifibrotic therapy can restore the normal functioning condition of the liver. LF has an antiviral effect against a wide variety of viruses, including hepatitis C. LF prohibited hepatocellular necrosis and showed a direct cytoprotective function in the liver. In a recent study on rats using thioacetamide (TAA), a model that revealed LF antifibrotic potentiality against liver fibrosis resembles human liver fibrosis [95].

Aerosolized bovine LF diminishes infection, inflammation, and iron imbalance in a cystic fibrosis mouse model of Pseudomonas aeruginosa mediated chronic lung infection [96]. Chronic airway infections are often sustained by Pseudomonas aeruginosa [97][98]. P. aeruginosa mediated chronic infection associated with decreased lung function as well as increased morbidity and mortality [99]. Along with infection, inflammation, and instability of iron homeostasis in CF airways and high levels of iron (up to >100 µM) in airway secretions has been observed [100-102]. Above all, increased expression of ferroportin (Fpn), ferritin (Ftn), and transferrin (Tf) were observed in the lung tissue of CF patients, which together with accumulated high levels of iron in the lower respiratory tract of CF subjects [102-104]. Excessive iron in CF airways increases growth and the biofilm lifestyle of P. aeruginosa, thus exacerbates inflammatory conditions and host injury [105-106]. LF can chelate two Fe3+ ions per molecule with high affinity, which is synthesized by exocrine glands and neutrophils at infection and inflammation sites. bLF is a milk derivative, with which it shares a high sequence homology of human proteins that looks identical with characteristics [107]. The bLF prevents host cell invasion by specific intracellular attachments or obligate bacterial pathogens[108-110]. It employs a strong anti-inflammatory activity that contributes to protecting mucus from inflammatory damage [108-112]. Treatment with aerosolized bLF or saline after infection proved that aerosolized bLF effectively reduced bacterial lung load and infiltrated leukocytes in infected CF mice. By reducing pulmonary iron overload in both wild-type (WT) and CF mice, bLF acts as a powerful multi-targeting agent capable of breaking down the cycle induced by P. aeruginosa, inflammation, and iron imbalance, thereby reducing the severity of CF-related pathology [96].

ER stress

The ER is a protein-folding apparatus which is made up of protein chaperones. ER catalyzes protein folding and senses the existence of misfolded or unfolded proteins [113]. Pathological evidences exhibited that ER stress is a common cause of many diseases where the stress is so severe or chronic that cells may die or damage [114]. Cellular dysfunction and cell death often occur when ER stress is prolonged, and a load of proteins in the ER exceeds its folding capacity [115]. Disruption of the ER's normal functions lead to an evolutionary preserved cell stress response, an unfolded protein response, which is primarily intended to compensate for damage but can ultimately lead to cell death due to severe or chronic ER dysfunction [116].

LF prevents oxidative stress and ER stress in the liver tissues of ob/ob mice. In that experiment, leptin-deficient (ob/ob) mice were used as rodent models of NAFLD (non-alcoholic fatty liver disease). Remarkably, ER stress has been currently recognized as a reason for controlled iron homeostasis via the contribution of hepcidin induced obesity and hepatic lipid accumulation. To evaluate LF's hepatoprotective effects, recombinant human LF is administered by intraperitoneal injection to alleviate or delay the pathological process of NAFLD. It is shown that the activation of ERK1/2 and elf2α, like NF-κB activation and oxidative stress, was seemingly blocked in the liver tissues of LF-treated ob/ob mice compared with vehicle-treated ob/ob mice. As a result, it recommends that LF's cytoprotective role may be related to ER stress prevention. It is indicated that hepatosteatosis-induced ER stress can be prevented by LF administration because the expression levels of hepatic p-elf2α and p-NF-κB were considerably
higher in ob/ob mice than in wild-type (WT) or LF-treated ob/ob mice. It has been shown that LF may be responsible for inhibition of ER stress and progression of autophagy of damaged hepatocytes and induction of up-regulation of hypoxia-inducible factor-1α/vascular endothelial growth factor (HIF-1α/VEGF) to assist liver function recovery due to its cytoprotective role [117].

**Autophagy dysfunction**

Autophagy is an intracellular degradation and energy recycling system, plays crucial roles in the immune responses and abnormal pathways that have been related to numerous disease conditions [118]. Typically, it is activated in nutritional deprivation conditions through the mTOR and AMPK signaling pathways to improve cell survival [119-121]. Autophagy dysfunction is defined as extreme autophagy initiation or block of autophagy flux, which cause possible cell death process, resulting in apoptosis or autophagic cell death [122].

LF induce autophagy by activating AMPK and inhibiting the Akt/mTOR Pathway. Cells were treated with different concentrations of LF and determined that LF augmenting autophagy in HK-2 cells (a human kidney proximal tubular epithelial cell line). It was observed that LF did not cause apparent cell function changes, but high concentrations of LF (200 µg/mL and 400 µg/mL) slightly improved HK-2 cells’ viability. Besides, western blot analysis of autophagy-related proteins predicts that LF induces autophagy [94]. It is reported that levels of beclin-1 and LC3-II were significantly raised in cells treated with LF. Furthermore, determining the percentage of punctate LC3-stained cells by fluorescence microscopy showed that LF treatment caused a concentration-dependent increase in LC3 dots in HK-2 cells. Another previous study also reported that autophagy induction could be regulated by activating AMPK and blocking the Akt/mTOR pathway. LF enhances AMPK phosphorylation and inhibits Akt and mTOR phosphorylation. Moreover, increased beclin-1 and LC3-II expression are caused by forced expression of the exogenous LF gene. These investigations specify that LF induces autophagy by activating AMPK and inhibiting the Akt /mTOR pathway. Augmenting autophagy in HK-2 cells, LF inhibits oxidative stress-induced cell death and apoptosis [94].

**Mitochondrial dysfunction**

Mitochondria are vital organelles of different cell types that play a significant role in cell survival and apoptotic cell death [123]. The definition of mitochondrial dysfunction is defined as the inability of mitochondria to produce and maintain adequate ATP levels through oxidative phosphorylation in response to energy needs [124][125]. Mitochondrial dysfunction is related to ROS-mediated damage [126][127]. A variety of degenerative diseases occurred due to mitochondrial oxidative injury. In neurodegenerative disorders, oxidative stress-induced neurodegeneration is occurred by ROS generation [128]. Oxidative stress is the leading cause of mitochondrial-mediated apoptotic cell death. Abnormal regulation of mitochondrial dynamic proteins can lead to neuropathological changes in prion disorders due to mitochondrial dysfunction. Neurodegenerative diseases like Prion disorder are caused by the accumulation of prion protein (PrP) scrapie isoform (PrPsc) in the central nervous system. PrPsc mediates neuronal cell death by raising the intracellular production of ROS [126].

LF has antioxidant capability due to the scavenging of ROS. LF treatment prevents against PrP -induced neuronal cell death and reduces ROS production. Decreased ROS production stopped PrP -induced mitochondrial dysfunction. Furthermore, PrP -induced protein activation and c-Jun N-terminal kinase and caspase-3 were inhibited by LF treatment [123]. Significantly, LF protects against mitochondrial dysfunction in the liver and other organs by decreased release of H2O2 from mitochondria. Also, LF protects against the development of insult-induced SIRS and its progression into septic conditions in vivo [129]. LF can diminish oxidative insult at the cellular and tissue levels after lipopolysaccharide exposure through the possible mechanism. Acute inflammatory responses mediated by cell injury and cell death are responsible for SIRS progression into sepsis. Both apoptotic and necrotic cell death is firmly related to mitochondrial dysfunction. It frequently happened due to increased ROS generation, increased membrane permeability, loss of mitochondrion integrity, and cellular ATP levels [129]. LF pretreatment in cultured cells and animal (mice) model of endotoxemia showed decline in LPS-induced elevation of ROS levels, decreased damage to nuclear and mtDNA. Early LF administration may provide a comprehensive protection from mitochondrial dysfunction.
It was currently revealed that LF could stop the progression of SIRS into sepsis in endotoxemic mice. LF pretreatment of cells in a dose-dependent manner reduces LPS-mediated oxidative insults. Pretreatment of LF in experimental animals considerably (P<0.05) depressed LPS-induced mitochondrial dysfunction in vivo. Notably, LF can prevent mitochondrial ROS generation and the accumulation of oxidative damage in the DNA. It has been shown that LF pretreatment reduced the release of H2O2 and DNA damage in the mitochondria. Thus, LF can be a potential option for the prevention and treatment of SIRS [129].

**Figure 2.** Pharmacological potentials of lactoferrin against pathological conditions. The diagram illustrates the complex pharmacological potentials of LF in relation to pathological disorders, including fibrosis, oxidative stress, endoplasmic reticulum (ER) stress, autophagy dysfunction, mitochondrial dysfunction, and inflammation. In renal fibrosis and liver fibrosis, LF has been shown to play an antifibrotic role. It maintains the physiological balance of ROS activity and protects cells from oxidative damage in a variety of pathological conditions. Lactoferrin reduces ER stress in ob/ob mice liver tissues. It has also been documented that it stimulates autophagy by activating several pathways in order to avoid autophagy dysfunction and apoptosis. Lactoferrin regulates the mitochondrial synthesis of H2O2 to protect the liver and other organs from mitochondrial dysfunctions. Its anti-inflammatory effects assist in the prevention of inflamed tissue inflammation as well as mediating host immunity.
CURRENT UPDATE ON CLINICAL TRIALS

Beside preclinical studies, clinical trial with LF is also undergoing (Table 2). A preliminary research indicates that LF may be a potential new oral iron replacement approach [130]. Some trials were performed based on the principal theory that oral bLF may decrease death risks or significant morbidities of preterm infants through its antioxidant, antimicrobial, and anti-inflammatory effects [131][132].

Table 2. Current update on clinical trials of LF.

<table>
<thead>
<tr>
<th>Identifier No.</th>
<th>Types of diseases</th>
<th>Estimated enrollment</th>
<th>Primary purpose</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04094597</td>
<td>Neonatal sepsis</td>
<td>200 participants</td>
<td>Prevention</td>
<td>Early Phase 1</td>
</tr>
<tr>
<td>NCT03431558</td>
<td>Neonatal sepsis, Necrotizing enterocolitis</td>
<td>300 participants</td>
<td>Prevention</td>
<td>Phase 3</td>
</tr>
<tr>
<td>NCT03163212</td>
<td>Safety issues Tolerance, Very low birth weight infant</td>
<td>20 participants</td>
<td>Treatment</td>
<td>Early Phase 1</td>
</tr>
<tr>
<td>NCT04445948</td>
<td>Helicobacter pylori infection</td>
<td>400 participants</td>
<td>Treatment</td>
<td>Phase 4</td>
</tr>
<tr>
<td>NCT03481790</td>
<td>Iron deficiency anemia of pregnancy</td>
<td>200 participants</td>
<td>Treatment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>NCT03202615</td>
<td>Anemia during pregnancy</td>
<td>130 participants</td>
<td>Treatment</td>
<td>Phase 4</td>
</tr>
<tr>
<td>NCT04267653</td>
<td>Iron deficiency anemia</td>
<td>96 participants</td>
<td>Treatment</td>
<td>Phase 4</td>
</tr>
<tr>
<td>NCT02959229</td>
<td>Neonatal sepsis</td>
<td>180 participants</td>
<td>Prevention</td>
<td>Phase 4</td>
</tr>
<tr>
<td>NCT04432935</td>
<td>Poliomyelitis</td>
<td>754 participants</td>
<td>Prevention</td>
<td>N/A</td>
</tr>
<tr>
<td>NCT01525316</td>
<td>Late-onset neonatal sepsis</td>
<td>414 participants</td>
<td>Prevention</td>
<td>Phase 3</td>
</tr>
<tr>
<td>NCT02626104</td>
<td>Antibiotic-associated diarrhoea</td>
<td>156 participants</td>
<td>Prevention</td>
<td>Phase 2</td>
</tr>
<tr>
<td>NCT01264536</td>
<td>Sepsis</td>
<td>190 participants</td>
<td>Prevention</td>
<td>Phase 2</td>
</tr>
<tr>
<td>NCT03866887</td>
<td>Iron-deficiency</td>
<td>288 participants</td>
<td>Treatment</td>
<td>N/A</td>
</tr>
<tr>
<td>NCT03367013</td>
<td>Preterm infant, Very low birth weight infant; Morbidity; newborn</td>
<td>500 participants</td>
<td>Prevention</td>
<td>Phase 3</td>
</tr>
<tr>
<td>NCT04435574</td>
<td>Anemia, iron deficiency</td>
<td>90 participants</td>
<td>Treatment</td>
<td>Phase 4</td>
</tr>
<tr>
<td>NCT01221844</td>
<td>Pregnancy, Iron deficiency, Iron deficiency anemia</td>
<td>300 participants</td>
<td>Treatment</td>
<td>Phase 4</td>
</tr>
<tr>
<td>NCT03940430</td>
<td>Iron deficiency anemia</td>
<td>90 participants</td>
<td>Treatment</td>
<td>Phase 3</td>
</tr>
<tr>
<td>NCT01266629</td>
<td>Crohn’s disease</td>
<td>40 participants</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>NCT00429325</td>
<td>Acute diarrhea</td>
<td>400 participants</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>NCT0097014</td>
<td>Infant nutrition</td>
<td>180 participants</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>NCT03262402</td>
<td>HIV/AIDS</td>
<td>22 participants</td>
<td>Treatment</td>
<td>N/A</td>
</tr>
<tr>
<td>NCT01700725</td>
<td>Persian-gulf syndrome, Chronic sinusitis, Fatigue, Acute sinusitis</td>
<td>40 participants</td>
<td>Treatment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>NCT00630656</td>
<td>Severe sepsis</td>
<td>190 participants</td>
<td>Treatment</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

FUTURE PERSPECTIVES AND CONCLUSIONS

LF is a multifunctional natural iron-binding protein. LF is widely active in different physiological processes, include metabolism of iron, antibacterial, antifungal, antiviral, antiparasitic, and anticarcinogenic functions. One of the primary features of LF is to scavenge free iron in biological fluids and ingrown regions in order to avoid free, easy-to-use, damage and reduce the involvement of metals to assault microbial and...
neoplastic cells. In other defensive mechanisms, LF plays a vital function, such as antioxidant prevention and protection against different kidney injuries. Also, LF is a cell-secreted mediator that links innate and adaptive immunity in mammals. LF binding affects the target cells in a cellular signaling pathway and activates the target genes. The pharmacological potential of LF against various pathological conditions, including oxidative stress, inflammation, fibrosis, ER stress, autophagy dysfunction, and mitochondrial dysfunction. Also, LF was found potential against various pathologies in clinical settings.

More research is eventually needed to better understand the role of LF in metabolism, especially in adipose tissues, lipolysis, and hepatic and intestinal lipid metabolism [133]. Study is also required to better understand the molecular features of LF in cancer localization [134]. This study provides insights into LF's protective role against various pathological mechanisms or conditions and outlines the updates on its clinical uses.

ACKNOWLEDGEMENTS
This work acknowledges National Research Foundation (No. 2020R111A1A01072879), and Brain Pool program funded by the Ministry of Science and ICT through the National Research Foundation (No. 2020H1D3A2A02110924), Republic of Korea.

AUTHOR CONTRIBUTIONS
This work is a collaboration among all the authors. MJU and AM designed outlines. KAA and ASMS wrote the initial draft of the manuscript. ASMS prepared the tables and illustrated the figures. MJU, SAMK, AM, KAA, and MRI edited and reviewed the scientific contents described in the manuscript. All authors read and approved the final submitted version of the manuscript.

CONFLICTS OF INTEREST
There is no conflict of interest among the authors.

REFERENCES
[22] Baker HM, Baker EN. A structural perspective on lactoferrin...


factor α or 1-methyl-4-phenylpyridinium treatment. Mol


[81] Zimecki M, Kocięba M, Kruzel M. Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology 2002;205:120–31.


[98] LiPuma JJ. The changing microbial epidemiology in cystic


This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.